Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635948 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4ETDP1SHMT2SMN1; SMN2 | |
| SCHEMBL29438234 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4ETDP1SHMT2SMN1; SMN2 | |
| SCHEMBL23582477 | 0.87 | SHMT2 (0.58) | ALDH1A1KDM4ESHMT2SMN1; SMN2HPGD | |
| SCHEMBL29913989 | 0.87 | SHMT2 (0.58) | ALDH1A1KDM4ESHMT2SMN1; SMN2HPGD | |
| SCHEMBL23582563 | 0.87 | SHMT2 (0.58) | ALDH1A1KDM4ESHMT2SMN1; SMN2HPGD | |
| SCHEMBL6869759 | 0.86 | MAPT (0.57) | ALDH1A1KDM4ESHMT2SMN1; SMN2HPGD | |
| SCHEMBL15037240 | 0.84 | SHMT2 (0.53) | ALDH1A1SHMT2SMN1; SMN2HTTTSHR | |
| SCHEMBL12184995 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4EGPBAR1L3MBTL1HSD17B10 | |
| SCHEMBL15022110 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4EGPBAR1L3MBTL1HSD17B10 | |
| SCHEMBL1089733 | 0.81 | CXCR4 (0.56) | ALDH1A1KDM4ESHMT2SMN1; SMN2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011143033-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | ALDH1A1 725/4885KDM4E 822/4885TDP1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.